Patient and public involvement prior to trial initiation: lessons learnt for rapid partnership in the COVID-19 era. by Jamal, Zahra et al.
RESEARCH ARTICLE Open Access
Patient and public involvement prior to
trial initiation: lessons learnt for rapid
partnership in the COVID-19 era
Zahra Jamal1* , Alexander Perkins1, Christopher Allen2, Research Advisory Group 1, Richard Evans1,
Joanna Sturgess1, Claire Snowdon1, Tim Clayton1 and Diana Elbourne1
Plain English summary
Patient and Public Involvement (PPI) describes the active involvement of patients and the public in the research
process. Through PPI, patients and members of the public are increasingly involved in the design and conduct of
clinical trials. PPI has been shown to improve the quality and relevance of research.
During the COVID-19 pandemic, clinical trials have been playing a vital role in helping us find ways to prevent and
treat the infection and improve our understanding of the virus. It is important that patients and the public are
actively involved in deciding how COVID-19 research is carried out. Unfortunately, Research Ethics Committees in
the UK have seen far less PPI for COVID-19 research studies compared with research before the pandemic. A key
reason for this is that research is being designed much faster than normal and researchers may feel they do not
have time to properly involve patients and the public.
In this paper, we share our experiences of PPI for a COVID-19 clinical trial. We show that it is possible to rapidly
involve patients and the public in COVID-19 clinical trials. We also explain how the design of the clinical trial was
changed in response to feedback from public contributors. Lastly, we discuss the wider learning from this process
which might be useful for researchers planning PPI activities for COVID-19 clinical trials in the future.
Abstract
Background: Clinical trials are playing a critical role in the global public health response to the COVID-19
pandemic. Despite the increasing recognition of the value of PPI in clinical trials, just 22% of the COVID-19 research
proposals reviewed by Research Ethics Committees in the UK at the start of the pandemic reported PPI. There is a
perception that PPI might result in delays in delivering research and therefore delays in obtaining important results.
In this paper, we report our experience of rapid PPI for a COVID-19 clinical trial.
Methods: RAPID-19 is a COVID-19 clinical trial which was planned to be submitted for fast-track ethics review in
the United Kingdom. During the development of the trial protocol, the PPI Panel at the London School of Hygiene
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& Tropical Medicine Clinical Trials Unit was involved in the design of the study. The meeting with the PPI Panel
lasted just over 1 h and was conducted by teleconference.
Results: Although we only had a short period of time to explore the study with the PPI Panel, we were able to
gain valuable insight into how the trial would be perceived by potential trial participants. Substantive changes were
made to the trial to improve the acceptability of the research without compromising the study timelines. Having
access to public contributors with relevant lived experience is an important resource for a Clinical Trials Unit and is
critical for rapid PPI. The move to remote working due to lockdown required virtual discussions which helped to
overcome some of the barriers to organising face-to-face meetings at short notice.
Conclusions: PPI for clinical trials can be conducted in a time-efficient manner within the pressured environment
of a pandemic. Involving PPI contributors at an early stage in protocol development maximised the opportunity to
shape and influence the trial as well as limited potential delays which could occur if changes to the protocol had
to be made at a later stage.
Keywords: Patient and public involvement, Clinical trials, COVID-19
Introduction
Patient and Public Involvement (PPI) in research
describes research which is “being carried out ‘with’ or
‘by’ members of the public” not just “‘to’, ‘about’ or ‘for’
them” [1]. There are compelling moral and practical
arguments for promoting active partnerships between
researchers and members of the public. The moral argu-
ment is that patients and the public have a right to be
involved in research that affects them. From a practical
perspective, PPI is understood to afford insights to re-
searchers that would not otherwise be available, in order
to improve the quality and relevance of studies.
PPI in clinical trials encompasses a range of activities
and types of involvement which can occur across all
stages of a study from conception to dissemination.
There is increasing recognition of the value of PPI in
clinical trials. A recent systematic review found that PPI
is likely to improve participant recruitment levels for
clinical trials [2].
Designing and conducting clinical trials in the context
of the COVID-19 pandemic presents many challenges
which include ensuring the active involvement of pa-
tients and the public in the research process. It is im-
portant that these challenges are addressed, as research
is playing a key role in the global public health response
to the pandemic. Well-conducted, high quality clinical
trials are critical to both our understanding of the virus
and in the development of diagnostic, prophylactic and
therapeutic products.
The crisis has sparked a wave of research activity. At
the time of submission of this paper, there have been
2489 COVID-19 studies registered on ClinicalTrials.gov
since the start of the pandemic [3]. In the UK, this has
been made possible through the development of new
procedures to provide swift reviews by Research Ethics
Committees for COVID-19 research. As a result, studies
can be reviewed within 24 h of submission [4].
It is important that with expedited trial design and ap-
provals, PPI in clinical trials is not neglected. Only 22%
of the COVID-19 research proposals submitting to Re-
search Ethics Committees (REC) in the UK in March
2020 included PPI compared with 80% of research
reviewed prior to the start of the pandemic [5].
The experience of conducting research during the
2014–15 West African Ebola epidemic showed that failure
to engage appropriately with communities led to distrust
and community backlash which, in turn, hindered early
research efforts [6]. On the other hand, an understanding
of the concerns of communities and an emphasis on
building relationships with them based on trust, mutual
respect and active involvement eventually helped to de-
liver successful Ebola trials [6].
The World Health Organization’s Good Participatory
Practice Guidelines for Trials of Emerging (and Re-
emerging) Pathogens emphasises the importance of
investing time to effectively engage stakeholders in the
research process [7]. However, the COVID-19 pandemic
represents a time-critical situation. By July 2020, the UK
had experienced one of the highest death tolls globally
from COVID-19 [8]. The urgency of the situation de-
mands that research seeking to answer key scientific
questions in understanding and tackling the pandemic,
including preparing for future outbreaks, be conducted
swiftly and efficiently.
In this paper, we present an example of PPI prior to a
COVID-19 clinical trial in the UK.
The clinical trial
Patients with cardiovascular disease, high blood pressure
and diabetes are at particularly high risk of poor outcomes
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from COVID-19 [9]. One possible explanation for this
increased risk lies in the medications used in the manage-
ment of these health conditions. ACE-inhibitors(ACEi)
and angiotensin receptor blockers (ARBs) are medications
commonly used to treat high blood pressure, diabetes and
heart failure. These medications increase the expression of
the receptor used by the COVID-19 virus to enter cells in
the body. However, the mechanism of this interaction in
influencing the severity of illness with COVID-19 is not
understood.
RAPID-19 is a pilot open-label randomised trial to
establish whether ACEi and ARBs affect the prognosis
and severity of illness in ambulatory patients with
COVID-19. Patients on ACEi/ARBs who present at
hospital with suspected or confirmed COVID-19, and
are considered well enough to return home to recover
from their COVID-19 symptoms, are eligible to take part
in the study. Participants with a confirmed diagnosis of
COVID-19 are randomised to either continue taking
their medications (control group) or to temporarily with-
draw ACEi or ARB for 14 days. Temporary withdrawal of
these medications is not associated with clinically signifi-
cant increases in blood pressure and participants will be
monitored for safety concerns. Participants are asked to
complete a daily diary for 14 days to monitor their symp-
toms. They are also followed up by telephone at 7 days,
14 days, and 30 days post-randomisation. Researchers are
available via telephone and in person to address concerns
and record adverse events.
RAPID-19 is a collaboration between King’s Health
Partners and the London School of Hygiene & Tropical
Medicine (LSHTM) Clinical Trials Unit (CTU). The trial
is sponsored by King’s College London. Although the
trial was submitted for ethical approval and the application
was granted a provisional opinion, the Trial Management
Group decided not to proceed with opening the trial. Cases
of COVID-19 had started to decline in the UK during the
first wave of infection which would have hindered recruit-
ment into the trial. In addition, other international trials
examining the same research question had also been set-up
and were already recruiting participants.
In accordance with the INVOLVE statement on public
involvement in research and research ethics committee
review [10], ethics approval was not sought for our pub-
lic involvement work on the clinical trial.
Methods
The RAPID-19 Trial Management Group (TMG) began
to develop a protocol for the trial which they planned to
submit for fast-track ethics review. The LSHTM CTU
has an established cardiovascular disease (CVD) PPI panel
(the Panel) comprising 10 members who have either lived
experience of CVD, or have direct experience as a carer or
family member to someone with CVD. The composition
of the Panel is diverse in terms of gender and ethnicity
and broadly reflective of the target population. The pur-
pose of the Panel is to work with the CTU in the design of
cardiovascular clinical trials to optimise the acceptability,
impact and relevance of studies.
We had only two working days to explore the RAPID-
19 Trial with the Panel and elicit feedback. It was agreed
to hold a meeting by teleconference to meet the needs
of all attendees. Prior to the meeting, the members were
emailed a written summary of the proposed trial design.
The meeting was attended by seven out of the ten mem-
bers of the Panel and lasted just over 1 h. A topic guide
was used to facilitate the discussions. The meeting was
not audio-recorded. In a separate meeting, we also
sought feedback on the trial from a patient representa-
tive on the National Cardiac Audit Programme. The
feedback from the meeting was written up by sorting
and arranging the comments from the Panel under the-
matic headings. Below we describe the insights offered
by PPI consultation and the actions taken in response.
The Guidance for Reporting Involvement of Patients
and the Public (GRIPP2) short form checklist was used
to guide the reporting of PPI in the paper [11].
Results
Risk assessment
A key issue raised by the Panel related to the interven-
tion itself. The intervention violates a common maxim
of medical advice, that one should not abruptly stop tak-
ing prescribed medications without consulting a doctor.
The contributors described their personal experiences of
changing or stopping medications. They explained that
this decision requires a discussion between their primary
care doctor and hospital consultant to examine the im-
pact and possible side effects of the regime change. A
decision to stop a medication may require the dose to be
reduced gradually over time.
In the trial scenario, the research staff may not have
access to the complete medical history of patients they
approach, and it may not always be practical to discuss
their case with relevant specialists. The Panel explained
that, in order to consider participating in the trial, they
would need to feel confident that the attending clinician
who offers recruitment into RAPID-19 has assessed their
clinical history and that, taking into account all relevant
information, the clinician is able to make an informed
assessment as to their suitability for the trial.
Clinical monitoring
PPI contributors remarked how the pandemic is creating
an exceptional backdrop for the conduct of research.
People are isolated from friends and family, some are
fearful of attending hospitals and terrified as to how the
virus may affect them. Participants will be feeling risk-
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averse and consequently need to feel assured that steps
have been taken to mitigate any risks to which they
could be exposed.
One concern raised by the Panel was that the level of
clinical monitoring provided by the trial does not satis-
factorily address the risk felt by participants told to stop
taking their medication. For example, how would partici-
pants know if their blood pressure becomes dangerously
high. There were mixed feelings about the usefulness of
home blood pressure monitors being provided to partici-
pants. Some felt that recording daily blood pressure
would be an additional burden and, even if training was
provided on using the monitors, participants may still
feel worried they are not using the device correctly.
Adherence to treatment arm
Members of the Panel commented that some partici-
pants may find it difficult adjusting to the change in
medication dictated by the intervention. One concern
was that participants who receive their medications in
pre-prepared dosette boxes from a pharmacy for multi-
drug regimens would need to identify and remove the
correct tablet from their blister pack. It was thought that
some patients accustomed to a set routine may forget
that they are under a new, altered drug regime and for-
get to remove the tablet.
The Panel also discussed whether automated mobile
phone messaging could be used to help participants
adhere to their allocated treatment. It was felt that, in
order to be effective, text messages would need to be
sent to coincide with the times participants normally
take their tablets and would therefore require custo-
mised messaging. The question was raised as to what to
do for participants who do not have mobile phones.
Response by TMG to evidence from the PPI panel
The TMG considered the evidence from the PPI panel
and used the insights gained to adapt the trial protocol
as follows:
Risk assessment
The TMG added a further exclusion criterion to the
eligibility criteria. It supports the case for the attending
clinician to assess, in conjunction with the patient and
on the basis of the patient’s clinical history, whether
their participation in the trial would put them at risk.
Patients who are considered at significant clinical risk
from participation in the trial would not be eligible to
take part.
Clinical monitoring
The TMG developed a daily patient diary for partici-
pants to use to monitor their symptoms (see Additional
file 1). The diary was provided to participants in paper
format. The records have been designed to alert the par-
ticipants if they experience any potentially harmful
symptoms that develop as a consequence of stopping
their medication. It is intended that these alerts would
prompt participants to contact the clinical team if they
experienced any worrying symptoms.
Adherence to treatment arm
The diary was also specifically designed to help partici-
pants remember a change in their medication by getting
them to complete their diary at the same time each day.
The diary asks participants if they have adhered to their
treatment allocation. Furthermore, the TMG decided to
exclude from the trial those patients who receive medi-
cation in a blister pack/dosette box.
Despite the short time-frame available, we were able
to gain valuable insight into how the trial would be per-
ceived by potential trial participants. The ability to feed
the views of the PPI Panel directly into the protocol,
with little delay to the REC application process, indicates
that a responsive process is possible and appropriate.
Discussion
Time constraint has been cited as a barrier to PPI in
research during the pandemic [12]. The experience
described in this paper demonstrates that valuable PPI
for clinical trials can be conducted in a time-efficient
manner within the pressured environment of a pan-
demic. The adaptations to the trial protocol, which were
made as a consequence of the PPI work, were vital for
improving the acceptability of the study to potential par-
ticipants and which may in turn help to support recruit-
ment and retention into the trial.
Key to this process was involving PPI contributors at a
very early stage which maximised the opportunity to
shape and influence the trial. This also limited potential
delays which could occur if changes to the protocol had
to be made at a later stage. Furthermore, conducting
thorough PPI during the development of the protocol
demonstrates to Research Ethics Committees that the
safety and wellbeing of patients is being taken into con-
sideration. This may help to reduce the number of
revisions required by RECs improving the efficiency of
the ethical review process (Health Research Authority:
HRA COVID-19 Public Involvement workshop summary,
unpublished).
The time required to identify appropriate public con-
tributors to be involved in the research process at short
notice can also be a barrier to PPI. In recognition of this
issue, the Health Research Authority has launched a
public involvement service for COVID-19 research stud-
ies applying for fast-track ethics review [13]. The service
provides guidance to researchers as to who they should
involve and what type of involvement they should seek,
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and then matches research teams with coordinators of
relevant public involvement groups across the UK.
We were fortunate to already have access to an active
PPI panel as well as individual public contributors. Hav-
ing an established PPI group is an invaluable resource
for a research team allowing researchers to respond
quickly to changing research priorities. We would there-
fore encourage Clinical Trials Units who do not have
access to public contributors to consider setting up their
own panel. In countries and settings where PPI is less orga-
nised and structured, public contributors could be accessed
through community-based organisations or using local
media and social media to promote PPI opportunities.
The members of our Panel have varying levels of
experience with PPI in clinical trials. Some PPI roles are
better suited to contributors with previous experience in
trials. However, providing feedback on early stage trial
development relies heavily on experiential knowledge
and we found that a lack of PPI trials experience was
not a barrier to contributing to discussions.
In addition, this contribution is enhanced through the
development of good working relationships both be-
tween the facilitators and PPI members, and between
the members themselves which provides the optimal
environment for rapid consultation work. Building
strong relationships with public contributors is particu-
larly important during the crisis as it is an anxious and
stressful time for all and especially for those groups with
underlying health conditions. The majority of members
of our Panel have significant health issues and, against
the background of the pandemic, the PPI process may
be particularly anxiety-provoking for some contributors.
PPI work conducted during this time offers opportun-
ities to understand that anxiety, but also requires a
mindful, respectful and emotionally sensitive approach
in order to avoid any exacerbation of concerns.
The Evidence Base for Public Involvement in Clinical
Trials (EPIC) study explores the different models of PPI
that can be applied to a trial [14]. The report concludes
that responsive and managerial roles for PPI contributors
such as membership of Trial Management Groups
(TMGs) are likely to bring greater benefit to the trial than
PPI contributors in oversight positions such as Trial Steer-
ing Committees. At the time of working on RAPID-19,
the CTU did not appoint PPI representatives to TMGs.
On reflection, we recognise that the study would have
benefitted from having a PPI representative on the TMG
to ensure continual PPI input throughout the develop-
ment of the trial. Furthermore, the TMG PPI representa-
tive could advise the TMG on using the feedback from
the Panel in adapting the trial protocol. As a result, the
CTU is now looking to expand the models of PPI that
we employ and are planning to appoint PPI representa-
tives to sit on the TMG in future trials.
The feedback from the Panel could also be supple-
mented with a rapid review of existing studies with trials
that explore relevant patient-acceptability themes applic-
able to the trial. Additionally, there is now a wealth of
on-the-ground experience emerging from COVID-19
clinical trials. New trials would benefit from incumbent
research teams sharing examples of good practice in
PPI, and how they have overcome challenges to build
knowledge and contribute to the evidence-base in this
field.
Researchers have been sharing their experiences and
best practice for online and remote co-production and
patient involvement, as well as the pros and cons of the
different virtual platforms available [15, 16]. Our PPI
meeting was initially planned to be held by videoconfer-
ence but some members of the Panel were not comfort-
able using digital platforms so we decided to conduct
the meeting using teleconference with a freephone num-
ber. The meeting was lively and animated and prompted
a lot of discussion. However, teleconferencing, unlike
with videoconferencing, does not give you the benefit of
non-verbal cues and it can be challenging to ensure that
everyone in the group has an opportunity to speak. We
followed up the meeting with an email to all attendees
asking them to phone the facilitator or to send any fur-
ther comments by email to ensure that we were able to
benefit from the contribution of all attendees. Following
the PPI panel meeting, the facilitator received one email
and one phone call from Panel members wanting to
provide further feedback on the trial as they had found
it difficult to share their comments during the telecon-
ference discussion.
Allowing PPI contributors to provide comment using
various modes of communication recognises that indi-
viduals have different communication styles with some
people preferring one-on-one conversation or giving
written feedback rather than group discussion. Further-
more, encouraging PPI members to get in touch after a
meeting gives contributors a period of reflection to
develop thoughts that might be stimulated by discussion.
Using WhatsApp, Microsoft Teams groups or other
communication media would provide a forum for such
discussion to continue after the meeting has ended.
Our PPI Panel meeting was held early in the course of
the pandemic when videoconferencing was not in com-
mon use. Since then, with the proliferation of digital plat-
forms, people have become much more familiar with
living and working virtually and increasingly PPI consulta-
tions are being conducted using videoconference. While
there are inherent challenges with working virtually, it
does offer opportunities. Even at the best of times, there
are a number of difficulties with organising face-to-face
meetings at short notice including the availability of some
members and especially those with caring responsibilities,
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the cost of travel and the fact that our Panel is geographic-
ally dispersed across England. Virtual meetings can offer
important solutions to these practical difficulties. In
addition, many videoconferencing platforms allow meet-
ings to be recorded which is helpful in producing detailed
notes from the discussions. Before a meeting is recorded,
researchers must obtain consent from all attendees and
adhere to organisational General Data Protection Regula-
tion policy [17]. Furthermore, new ways of working may
help to broaden the representation of the patients and
public involved in research and address the lack of diver-
sity of PPI contributors which has long been recognised as
a weakness of the PPI system [18].
We recognise there are costs involved for the Panel in
terms of time and energy. Given the disproportionate
impact of the pandemic on ethnic minorities, people
from low socioeconomic groups and older adults, it is
crucially important that these communities are
supported to become actively involved in COVID-19 re-
search. This will be critical for addressing the stark
health inequalities exposed by the crisis. Particular atten-
tion should be given to the possibility that digital modal-
ities might exclude certain communities from taking
part in PPI. Researchers working with underrepresented
groups must adopt a flexible approach and use a range
of communication approaches to ensure inclusivity.
PPI in research plays an important role in building
public trust in scientific evidence [19]. A survey con-
ducted by the Academy of Medical Sciences found that
only a third of the public trusts evidence generated
through medical research [19]. Crises create a climate of
fear and panic, where misinformation and distrust can
easily proliferate. Recent scandals during the pandemic,
including the well-publicised retraction of the Lancet
journal article on hydroxychloroquine [20] may further
erode trust in science. Lack of trust may not only com-
promise recruitment into critical clinical trials, but, can
also undermine the translation of that evidence into clin-
ical practice. This is an opportune time to capitalise on
the public’s heightened interest in research and science,
and to build research literacy which leaves a lasting leg-
acy to the wider society. Funders, Sponsors and Research
Ethics Committees must uphold PPI standards for
COVID-19 research including those for studies eligible
for fast-track review.
Limitations
This paper describes the lessons learnt for conducting
rapid PPI consultation from the perspective of the re-
search team. However, the PPI Panel have contributed
to the manuscript and are named in the authorship of
the paper. The findings presented in this paper could be
strengthened by using qualitative research to actively ex-
plore with the PPI contributors, their experience of rapid
PPI, the perceived impact of their involvement and to
consider how they feel the process could be improved.
Conclusion
The need for PPI is arguably more important now than
ever. Conducting research in partnership with patients
and members of the public will be critical for the
successful delivery of COVID-19 clinical trials. The
pandemic has accelerated change in clinical trials prac-
tices, driving trials and the review process to necessarily
become more streamlined and efficient. The ability to
conduct PPI in a time-efficient manner is not only
essential for research during this crisis and for respond-
ing to future public health emergencies, but should also
be applied beyond the pandemic.
We should leverage this newly-learned rapid engage-
ment between researchers and public contributors, and
the sharing of best practice developed during the
COVID-19 crisis to create a new era of patient and pub-
lic involvement for the benefit of future clinical trials
research.
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